Insider trade

Christopher Richard Anzalone, CEO at Arrowhead Pharmaceuticals, sold ~$11K of Arrowhead Pharmaceuticals shares.

~$11K
Approx. value · 166 sh @ $66.77
3.92M
Holds after · shares reported
Traded
Dec 16, 2025
Filed
Dec 16, 2025

What stands out in this filing

  • After this sale the filing reports 3,920,178 shares.
  • 166 shares at an average of $66.77 each, as reported on the form.
  • Footnote references vesting of compensation awards.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: reported its results, 21 days earlier (Nov 25, 2025). The first one after it: signed an important agreement, 22 days later (Jan 7, 2026).

  1. Company filing · Form 8-K · ResultsReported its results
  2. InsiderDirector sold ~$493K of ARWR shares in the open market
  3. InsiderDirector sold ~$992K of ARWR shares in the open market
  4. Insider · 1 personInsiders: 3 sales (~$9.0M)
  5. InsiderCEO sold ~$11K of ARWR shares in the open market

What came next

  1. Insider · 1 personInsiders: 8 sales (~$3.4M)
  2. Insider · 1 personInsiders: 4 sales (~$5.4M)
  3. Insider · 4 peopleInsiders: 12 sales (~$2.8M)
  4. Insider · 1 personInsiders: 2 sales (~$861K)
  5. InsiderDirector sold ~$527K of ARWR shares in the open market
  6. Insider · 1 personInsiders: 2 sales (~$3.6M)
  7. Insider · 1 personInsiders: 2 sales (~$872K)
  8. Insider · 2 peopleInsiders: 19 sales (~$5.7M)
  9. Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
  10. Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  11. Company filing · Form 8-K · ResultsReported its results
  12. InsiderOfficer sold ~$642K of ARWR shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Arrowhead Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Arrowhead Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARWR page.

Other recent filings by Christopher Richard Anzalone, Chief Executive Officer

The full history of Christopher Richard Anzalone, Chief Executive Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Arrowhead Pharmaceuticals (ARWR) insider traded, and how much?

Christopher Richard Anzalone, CEO at Arrowhead Pharmaceuticals, sold ~$11K of Arrowhead Pharmaceuticals shares. 166 shares at $66.77.

When did it happen, and when was it made public?

Traded: Dec 16, 2025. Filed: Dec 16, 2025.

What stands out in this filing?

After this sale the filing reports 3,920,178 shares. 166 shares at an average of $66.77 each, as reported on the form. Footnote references vesting of compensation awards.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean ARWR stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Arrowhead Pharmaceuticals

Everything OQRO holds on this company is on its ARWR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data